March 2025 Dr.Nakatsukasa's technical paper has been published.
Biomaterials Science. [Epub ahead of print] Antitumor immune response elicited by M2 TAM-specific DDS via C-type lectin CD209b using cholesteryl pullulan nanogel as a protein drug carrier. T Nakatsukasa, D Muraoka, S Deng, K Yasui, S Sawada, A Shimoda, H Matsushita, K Matsumoto, T Nagayasu, N Harada, K Akiyoshi, H Ikeda.
January 2025 Dr.Ikeda's technical paper has been published.
International Immunology. [Epub ahead of print] Cancer immunotherapy in progress-an overview of the past 130 years. H Ikeda.
8th-10th November 2024 the 39th Society for Immunotherapy of Cancer Annual Meeting(SITC)
Prof Ikeda attended the American Society for Cancer Immunotherapy (SITC) General Meeting held in Houston. He had a meaningful meeting with the SITC leadership team about building a collaborative relationship with the Japanese Association for Cancer Immunology (JACI). The SITC General Meeting was a great success, and I was impressed by the many excellent presentations. I would like to see more participants from Japan. I was also invited to lunch by professors at MD Anderson Cancer Center and young researchers at Okayama University, and had the opportunity to hear valuable stories about the situation of young researchers in Japan and the United States.
Picture1Picture2Picture3Picture4
19th-21th September 2024 We presented a paper at the 83rd Annual Meeting of the Japanese Cancer Association.
◆「Secretoglobin Superfamily Protein SCGB3A1 is a candidate tumor suppressor.」Dr.Yoneda
◆「Development of new adoptive T cell therapy that overcomes tumor heterogeneity with escape variant tumor clones.」Mr.Yasui
◆「TCR-T therapy overcomes tumor heterogeneity with escape variant tumor clones in combination with ferroptosis inducer.」Dr.Ehara
◆「TNFa-TNFR1 axis involvement in the overcoming of tumor heterogeneity in adoptive T cell therapy.」Mr.Tou
September 2024 Dr.Ikeda's research was adopted in AMED Project for Promotion of Cancer Research and Therapeutic Evolution.
Project「Study of CAR-T therapy targeting refractory solid tumors utilizing cancer-specific monoclonal antibodies」
September 2024 Mr.Muraoka's technical paper has been published.
npj Vaccines. [Epub ahead of print] Low-frequency CD8+ T cells induced by SIGN-R1+ macrophage-targeted vaccines confer SARS-CoV-2 clearance in mice D Muraoka, M Moi, O Muto, T Nakatsukasa, S Deng, C Takashima, R Yamaguchi, S Sawada, H Hayakawa, T Nguyen, Y Haseda, T Soga, H Matsushita, H Ikeda, K Akiyoshi, and N Harada.
10th-12th July 2024 We presented a paper at the 28th Annual Meeting of Japanese Association of Cancer Immunology and the 37th Annual Meeting of Japan Society for Biological Therapy.
「Development of new adoptive T cell therapy that overcomes tumor heterogeneity with escape variant tumor clones」 Mr.Yasui 写真
「Exploring the role of the TNFα-TNFR1 axis in elimination of tumor with heterogeneity through adoptive T cell therapy」 Mr.Tou 写真
22th-24th March 2024 We presented a paper at the 1st International Symposium on Cancer Immunology and Immunotherapy.
「TCR-T therapy combined with ferroptosis inducer overcomes tumor heterogeneity that consists of escape variants」Dr.Ehara picture1picture2
17th-23th February 2024 Prof.Ikeda discussed the exchange program and signed the agreement in University of Montana. picture1picture2picture3
1st January 2024 The Article Dr.Ikeda's research was published on the science newspaper(No.3952). article
19th January 2024 Dr.Ikeda presented a paper at the 53th Annual Meeting of the Japanese Society for Immunology
September 2023 Dr.Nakatsukasa received the "JCA Young Researcher Poster Award".
◆Photo◆
「Molecular mechanism of the drug delivery targeted to tumorassociated macrophages by cholesteryl pullulan nanogels」
21-23 September 2023 We presented a paper at the 82nd Annual Meeting of the Japanese Cancer Association.
◆Mr.Yasui , Dr.Nakatsukasa , Dr.Ehara , Mr.Deng
◆Photo◆
2nd September 2023 Oncology Symposium2023 was held.
◆program
◆Photo
◆time：PM2:00～PM5:30
◆place：4th floor Tropical Medicine and GlabalHealth building in Nagasaki University
September 2023 This paper has been published. Cancer Science
2023 Sep 7. doi: 10.1111/cas.15954. Online ahead of print. T cell receptor gene-modified allogeneic T cells with siRNA for endogenous T cell receptor induce efficient tumor regression without graft-versus-host disease S Okada,D Muraoka,K Yasui,I Tawara,A Kawamura,S Okamoto,J Mineno,N Seo,H Shiku,S Eguchi, H Ikeda
19-21 July 2023 We presented a paper at the 27rd Annual Meeting of Japanese Association of Cancer Immunology.
◆Mr.Yasui , Dr.Nakatsukasa , Dr.Ehara , Mr.Deng
12th April 2023 We are discussed with teachers from Montana University. picture
19th Febrary 2023 Dr.Ikeda presented a paper at the 33rd Annual Meeting of the Japan Broncho-esophagological Society for Board Certified Physicians
November 2022 This paper has been published. BMJ Open
2022 Nov 14;12(11):e065109. doi: 10.1136/bmjopen-2022-065109. Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer: protocol for a multi-institutional phase 1 clinical trial.
S Okumura, M Ishihara, N Kiyota, K Yakushijin, K Takada, S Kobayashi, H Ikeda, M Endo, K Kato, S Kitano, A Matsumine, Y Nagata, S Kageyama, T Shiraishi, T Yamada, K Horibe, K Takesako, H Miwa, T Watanabe, Y Miyahara, H Shiku
12th October 2022 Prof.Ikeda presented a paper at the 6th International Workshop on Humanized Mice.
◆「Development of adoptive T cell therapy for cancer patients utilizing humanized mice」
29th.September-1st October 2022 We presented a paper at the 81th Annual Meeting of the Japanese Cancer Association.
◆「Development of cancer immunotherapy using "stealth T cells" to overcome tumor heterogeneity.」 by Mr.Yasui
◆「Identification of the receptor molecules for the drug delivery system 'CHP nanogels'.」 by Dr.Nakatsukasa
◆「Development of adoptive cell therapy that overcomes tumor heterogeneity utilizing immune cell-death inducer (IDI).」 by Dr.Ehara
◆「Small molecule tuning T cell activation threshold via electron transport chains leads the anti-tumor effect.」 by Mr.Muraoka
20-22 July 2022 We presented a paper at the 26rd Annual Meeting of Japanese Association of Cancer Immunology.
◆Dr.Nakatsukasa , Dr.Dotsu
16th July 2022 Dr.Ikeda presented a paper at the 28th Annual Meeting of Japan Society of Gene and Cell Therapy
「Harnessing TCR-T therapy to overcome personalization and tumor heterogeneity」
June 2022 This paper has been published. Journal for immunotherapy of cancer
2022 Jun;10(6):e003811. doi: 10.1136/jitc-2021-003811 NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
M Ishihara, S Kitano, S Kageyama, Y Miyahara, N Yamamoto, H Kato, H Mishima, H Hattori, T Funakoshi, T Kojima, T Sasada, E Sato, S Okamoto, D Tomura, I Nukaya, H Chono, J Mineno, Muhammad Faris Kairi, Phuong Diem Hoang Nguyen, Yannick Simoni, Alessandra Nardin, Evan Newell, Michael Fehlings, H Ikeda, T Watanabe, H Shiku
12th April 2022 Dr.Ikeda's comment was published on the Toyama newspaper article
April 2022 Dr.Nagata's technical paper has been published. Cancer Immunology, Immunotherapy.
2022 Apr 16. doi: 10.1007/s00262-022-03194-5 Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1–vaccinated patients as adjuvant therapy
Nagata Y, Kageyama S, Ishikawa T, Kokura S, Okayama T, Abe T, Murakami M, Otsuka K, Ariyoshi T, Kojima T, Taniguchi K, Kobayashi S, Shimada H, Yajima S, Suzuki T, Hirano S, Tsuchikawa T, Shichinohe T, Ueda S, Kanetaka K, Yoneda A, Wada H, Doki Y, Yamaue H, Katsuda M, Ohi M, Yasuda H, Kondo K, Kataoka M, Kodera Y, Koike M, Shiraishi T, Miyahara Y, Goshima N, Fukuda E, Yamaguch K, Sato E, Ikeda H, Yamada T, Osako M, Hirai K, Miyamoto H, Watanabe T, Shiku H
February 2022 Dr.Dotsu's technical paper has been published. Journal for immunotherapy of cancer.
2022 Feb;10(2):e003958. doi:10.1136/jitc-2021-003958 Chemical augmentation of mitochondrial electron transport chains tunes T cell activation threshold
in tumors
Yosuke Dotsu , Daisuk Muraoka,Naohisa Ogo,Yudai Sonoda,Kiyoshi Yasui,Hiroyuki Yamaguchi,Hideo Yagita,Hiroshi Mukae,Akira Asai,Hiroaki Ikeda
1st January 2022 The Article Dr.Ikeda's research was published on the science newspaper(No.3855). article
November 2021 Dr.Ikeda's research was adopted in AMED Science and Technology Platform Program for Advanced Biological Medicine.
Project「Development of cancer-specific antibodies for refractory cancers and its clinical application」
30th.September-2nd October 2021 We presented a paper at the 80th Annual Meeting of the Japanese Cancer Association.
◆Dr.Ikeda , Dr.Dotsu , Dr.Nakatsukasa , Dr.Ehara , Mr.Tou
September 2021 Dr.Dotsu's technical paper has been published.
Journal of Clinical Medicine.
2021 Sep 17;10(18):4221. doi: 10.3390/jcm10184221 Real-world Incidence of Febrile Neutropenia among Patients treated with Single-agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-stimulating Factor
Yosuke Dotsu, Hiroyuki Yamaguchi, Minoru Fukuda, Takayuki Suyama, Noritaka Honda, Yasuhiro Umeyama, Hirokazu Taniguchi, Hiroshi Gyotoku, Shinnosuke Takemoto, Ryuta Tagawa, Ryosuke Ogata, Hiromi Tomono, Midori Shimada, Hiroaki Senju, Katsumi Nakatomi, Seiji Nagashima, Hiroshi Soda, Hiroaki Ikeda, Kazuto Ashizawa, Hiroshi Mukae
3rd September 2021 Dr.Ikeda presented a paper at the 29th Japanese Society for Histocompatibility and Immunogenetics.
July 2021 The research was adopted in Nagasaki University contribution.
「COVID-19 vaccine development」
◆Dr.Ikeda , Mr.Muraoka , Mr.Yasui
1-3 July 2021 We presented a paper at the 25rd Annual Meeting of Japanese Association of Cancer Immunology.
◆Mr.Yasui , Dr.Dotsu , Dr.Ehara
June 2021 Dr.Nakatsukasa received the "2021 Nagasaki Medical Alumni Association Grant".
20 March 2021 Dr.Ikeda presented a paper at the 23th Education Seminar of Japanese Society of Gastroenterology Program
November 2020 Dr.Dotsu's technical paper has been published.
Thoracic Cancer. 2021 Jan;12(2):272-276. doi: 10.1111/1759-7714.13756. Dabrafenib and trametinib therapy for an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation Yosuke Dotsu, Minoru Fukuda, Noritaka Honda, Hiroshi Gyotoku, Yoshihisa Kohno, Takayuki Suyama, Yasuhiro Umeyama, Hirokazu Taniguchi, Shinnosuke Takemoto, Hiroyuki Yamaguchi, Taiga Miyazaki, Noriho Sakamoto, Yasushi Obase, Hiroaki Ikeda, Kazuto Ashizawa, Hiroshi Mukae
October 2020 Mr.Muraoka's technical paper has been published.
Vaccine. 2020 Nov 17;38(49):7697-7701. doi: 10.1016/j.vaccine.2020.10.039. Epub 2020 Oct 19. Identification of a dominant CD8+ CTL epitope in the SARS-associated coronavirus 2 spike protein DaisukeMuraoka, Deng Situo, Shin-ichi Sawada, Kazunari Akiyoshi, NaozumiHarada, HiroakiIkeda.
7-9 October 2020 We presented a paper at the 24rd Annual Meeting of Japanese Association of Cancer Immunology. Photo
◆Mr.Yasui , Dr.Dotsu
1-3 October 2020 >We presented a paper at the 79th Annual Meeting of the Japanese Cancer Association.
◆Dr.Ikeda , Mr.Muraoka
July 2020 We started to resurch about COVID-19 vaccine. Prerelease
26 June 2020 (June 25, 6:00 PM United States Eastern Time) Dr.Ikeda presented a paper at Society of Toxicology
「 Can We Predict and Manage Immune-Related Adverse Events Associated with Cancer Immunotherapy? 」
May 2020 Dr.Dotsu received the "2020 Nagasaki Medical Alumni Association Grant".
2020 Dr.Ikeda's technical paper has been published.
Cancer Science.
CD4+ T cells support polyfunctionality of cytotoxic CD8+ T cells with memory potential in immunological control of tumor.
Naoko Imai, Isao Tawara, Makiko Yamane, Daisuke Muraoka, Hiroshi Shiku, Hiroaki Ikeda.
5 October 2019 Mr.Muraoka presented a paper at The 11th Annual Meeting of Japanese Society of Immunotherapy for Hematological Disorders. Program
26-28 September 2019 We presented a paper at the 78th Annual Meeting of the Japanese Cancer Association.
◆Mr.Muraoka , Dr.Dothu
21-23 August 2019 We presented a paper at the 23rd Annual Meeting of Japanese Association of Cancer Immunology.
◆Dr.Ikeda , Mr.Muraoka , Mr.Yasui , Dr.Dothu
23-25 May 2019 Dr.Ikeda presented a paper at the 67th Annual Meeting of Japan Society of Transfusion Mediceine and cell Terapy.
17-18 May 2019 Dr.Ikeda presented a paper at the 10th JSH International Symposium.
「Development of Adoptive Cell Therapy with Allogeneic TCR Gene-modified “Stealth T cells” Deficient in Endogenous TCR and HLA Class I Molecules.」Dr.Ikeda
15-16 April 2019 Dr.Ikeda presented a paper at the 3rd Joint Symposium between Nagasaki University and Würzburg University.
「Adoptive cell therapy with gene-engineered T cells for cancer patients」 Program(English) Program(Japanese) Photo
4-5 April 2019 Dr.Ikeda presented a paper at the 2nd Nagasaki-LUMC Symposium.
「Development of novel adoptive immunotherapy of cancer with gene-engineered T cells」 Program Photo
22 March 2019 Mr.Muraoka received the "Nagasaki Science and Technology encouragement Award".
There was Awards ceremony at Nagasaki Prefectual office and he announced reseach results to Nagasaki prefectural governor. web site of Prefectualoffice
February 2019 The Article Mr.Muraoka's research with Kyoto University was published on newspapers. Yomiuri Newspaper Kyoto Newspaper
January 2019 Mr.Muraoka's technical paper has been published.
The Journal of Clinical Investigation. 2019 Jan 10. pii: 97642. doi: 10.1172/JCI97642.
Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. Daisuke Muraoka, Naohiro Seo, Tae Hayashi, Yoshiro Tahara, Keisuke Fujii, Isao Tawara, Yoshihiro Miyahara, Kana Okamori, Hideo Yagita, Seiya Imoto, Rui Yamaguchi, Mitsuhiro Komura, Satoru Miyano, Masahiro Goto, Shin-ichi Sawada, Akira Asai, Hiroaki Ikeda, Kazunari Akiyoshi, Naozumi Harada, and Hiroshi Shiku.
13-14 October 2018 >We presented a paper at the 80th Annual Meeting of Japanese Society of Hematology. Photo
「Adoptive therapy with TCR-gene modified T cells for treatment of patients with hematological malignancy and solid tumors」 Dr.Ikeda
27-29 September 2018 We presented a paper at the 77th Annual Meeting of the Japanese Cancer Association. Photo
◆Mr.Muraoka , Dr.Okada
1-3 August 2018 We presented a paper at the 22nd Annual Meeting of Japanese Association of Cancer Immunology.
◆Dr.Ikeda , Mr.Muraoka , Dr.Okada
19 July 2018 Ms.Karino is selected as research seminar student.She will study abroad in January-March 2019. detail
Nagasaki University School of Medicine Research Abroad Program 2018
23 June 2018 Oncology Symposium2018 was held. program Photo
time：PM1:00～PM6:00
place：1st floor Tropical Medicine and GlabalHealth building in Nagasaki University
May 2018 Mr.Yasui's technical paper has been published.
Biochem Biophys Res Commun. 2018 Apr 20. pii: S0006-291X(18)30940-9. doi:10.1016/j.bbrc.2018.04.159. [Epub ahead of print]
MicroRNA-3662 expression correlates with antiviral drug resistance in adult
T-cell leukemia/lymphoma cells. Yasui K, Izumida M, Nakagawa T, Kubo Y, Hayashi H, Ito T, Ikeda H, Matsuyama T.
7 May 2018
Department of ONCOLOGY, Nagasaki University Graduate School of Biomedical Sciences website was opened.
